Which adverse effects are associated with valproate used for migraine prevention?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Valproate has two especially important adverse effects to remember in migraine prevention: hepatotoxicity and teratogenicity. Hepatotoxicity can lead to serious liver injury, and the risk is higher in young children, in patients with certain metabolic or mitochondrial conditions, and when used with other antiepileptic drugs. This makes baseline liver function tests and periodic monitoring essential, with attention to symptoms like fatigue, vomiting, abdominal pain, or jaundice that might signal liver trouble. Teratogenicity is a major concern because valproate markedly increases the risk of neural tube defects and other congenital anomalies, as well as later cognitive and developmental problems in the exposed child. Because of this, valproate is generally avoided in women who could become pregnant; if it must be used, strict contraception, patient counseling, use of the lowest effective dose, and folic acid supplementation before conception are important.

Other adverse effects like weight gain or sedation can occur but do not define the key safety considerations for valproate in migraine prevention, and hypertension, edema, hypoglycemia, or diarrhea are not the characteristic risks associated with this drug.